A Study of CPI-0209 in Patients With Advanced Tumors
Status:
Recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in
patients with advanced tumors alone and in combination with other therapies. CPI-0209 is a
small molecule inhibitor of EZH2.